Sat Kartar Life Limited (SATKARTAR)
Q2 FY27 results
📅 Next results: 24 Oct 2026 (board meeting)Sat Kartar Life Limited's board meets on 24 Oct 2026 to consider its Q2 FY27 results (July-September 2026).
In its latest reported quarter, H2 FY26, Sat Kartar's revenue was ₹111 Cr, and net profit ₹9.8 Cr; the operating margin was 13.4%.
| H2 FY26 (₹ Cr) | Value | YoY | vs prev. half |
|---|---|---|---|
| Revenue | ₹111 | — | — |
| Operating profit | ₹14.9 | — | — |
| Net profit | ₹9.8 | — | — |
| EPS (₹) | 6.22 | — | — |
| Operating margin | 13.4% | — | — |
SATKARTAR delivery percentage
NSE end-of-day data for
On Fri, 16 Oct 2026, 58.97% of the SATKARTAR shares traded on NSE were taken to delivery, against the stock's own 20-session average of 70.73%. That is lower than usual for this stock. It closed at a price band (circuit) on 5 sessions in about the last 20.
Delivery in the last 5 sessions: 54.0% · 70.0% · 85.4% · 63.7% · 59.0%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Sat Kartar Life Limited issued a corrigendum to its October 23, 2026 EGM notice following observations from the NSE regarding its proposed preferential issue of convertible warrants. The company clarified that 5,50,000 convertible warrants are proposed to be allotted to the promoter group, including Manprit Singh Chadha (3,50,000), Archana Chadha (1,75,000), and Simrati Kaur (25,000). The fully diluted post-issue equity base will expand to 1,91,80,076 shares, incorporating 1,39,600 ESOPs and 26,95,200 previously issued warrants. Consequently, total promoter holding will decrease from 63.45% pre-issue to 55.12% on a fully diluted basis, with no change in management control.
- Proposed allotment of 5,50,000 convertible warrants to promoter and promoter group members
- Post-issue fully diluted equity base increases to 1,91,80,076 shares
- Total promoter shareholding shifts from 63.45% pre-issue to 55.12% post-issue on a fully diluted basis
- Fully diluted calculation includes 1,39,600 ESOPs and 26,95,200 non-promoter warrants from May 2026
- EGM scheduled for October 23, 2026 via VC/OAVM to seek shareholder approval
Sat Kartar Life Limited has issued a notice convening an Extraordinary General Meeting (EGM) on October 23, 2026, to seek shareholder approval for issuing up to 5,50,000 fully convertible warrants on a preferential basis to the promoter/promoter group. The warrants are priced at ₹172 each, totaling up to ₹9.46 crore. A minimum of 25% (₹2.365 crore) is payable on subscription, with the remaining 75% (₹7.095 crore) due upon warrant conversion within 18 months. The cut-off date for e-voting is October 16, 2026.
- Proposed issuance of up to 5,50,000 fully convertible warrants at ₹172 each to the promoter/promoter group
- Total capital planned to be raised is up to ₹9.46 crore (₹9,46,00,000)
- 25% upfront subscription payable equals ₹2.365 crore (₹2,36,50,000), with 75% (₹7.095 crore) upon conversion within 18 months
- E-voting period runs from October 20, 2026 to October 22, 2026, ahead of the EGM on October 23, 2026
Sat Kartar Life Limited's Board has approved the issuance of up to 5,50,000 convertible warrants on a preferential basis to promoter group entities, raising up to ₹9.46 crore. The issue price is fixed at ₹172 per warrant, which is an 18.20% premium over the SEBI ICDR floor price of ₹145.51. Upon full conversion within 18 months, promoter shareholding will increase from 54.20% to 55.52%. The company has scheduled an Extraordinary General Meeting (EGM) on October 23, 2026, to seek shareholder approval, with a voting cut-off date of October 16, 2026.
- Preferential issuance of up to 5,50,000 convertible warrants at ₹172 each, totaling ₹9.46 crore
- Issue price is at an 18.20% premium above the SEBI ICDR floor price of ₹145.51
- Promoter holding to increase from 54.20% to 55.52% post full conversion
- 25% upfront subscription payable immediately, with the remaining 75% due within an 18-month tenure
- Shareholder approval to be sought at an EGM on October 23, 2026 (cut-off date: October 16, 2026)
Sat Kartar Life Limited's board has approved the issuance of up to 5,50,000 convertible warrants at ₹172 each, raising up to ₹9.46 crore on a preferential basis. The warrants are being allocated exclusively to members of the promoter and promoter group at an 18.20% premium over the SEBI floor price of ₹145.51. Upon full conversion within the 18-month tenure, promoter shareholding will rise from 54.20% to 55.52%. The company has convened an Extra Ordinary General Meeting on October 23, 2026, to seek shareholder approval.
- Approved issuance of 5,50,000 convertible warrants aggregating up to ₹9,46,00,000
- Issue price set at ₹172 per warrant, representing an 18.20% premium over the SEBI floor price of ₹145.51
- Promoter holding to increase from 54.20% (1,00,21,556 shares) to 55.52% (1,05,71,556 shares) post full conversion
- 25% payable upfront upon subscription, with remaining 75% payable within an 18-month warrant tenure
- Shareholder approval scheduled via EGM on October 23, 2026, with cut-off date set as October 16, 2026
Sat Kartar Life Limited has signed a Letter of Intent (LOI) to establish a new 20-bed hospital-cum-therapy centre on Rajpur Road, Dehradun, Uttarakhand. The facility will span approximately 7,000 sq. ft. with an estimated investment of ₹70 Lakh funded via IPO funds. It is targeted to be operational by December 15, 2026, subject to regulatory approvals. This move aligns with the company's stated strategy to vertically integrate into high-margin (25-30% EBITDA) Ayurvedic hospital services.
- Signs Letter of Intent for a 20-bed Hospital-cum-Therapy Centre in Dehradun, Uttarakhand
- Facility spread across approximately 7,000 sq. ft. with an estimated investment of ₹70 Lakh
- Funded through IPO funds, targeted to be operational by December 15, 2026
- Supports strategic expansion into Ayurveda-based therapies and integrated wellness
Sat Kartar Life Limited has scheduled an analyst visit and management interaction at its Sat Kartar Sanjeevan Hospital in Paschim Vihar, New Delhi, on Wednesday, September 9, 2026, at 11:00 AM. The group interaction is organized by Merlin Capital Advisors with 7 participating firms, including Alpha AMC, Green Portfolio, and Swaraj Holdings. The company noted that no unpublished price sensitive information (UPSI) will be shared during the visit.
- Hospital site visit and management interaction scheduled for September 09, 2026, at 11:00 A.M.
- Interaction venue is Sat Kartar Sanjeevan Hospital, Plot No. 18, Paschim Vihar Extension, New Delhi.
- 7 participating analyst/institutional firms organized via Merlin Capital Advisors.
- Company confirmed no Unpublished Price Sensitive Information (UPSI) will be shared.
Sat Kartar Life Limited announced that its shareholders have approved the re-appointment of M/s. Nidhi Bansal & Co., Chartered Accountants, as the Statutory Auditor of the company for a term of 5 consecutive years. The approval was confirmed via e-voting results following the Annual General Meeting held on August 28, 2026. The auditing firm brings over 18 years of professional experience across accounting, auditing, and tax advisory.
- Re-appointment of M/s. Nidhi Bansal & Co. as Statutory Auditor approved for a period of 5 consecutive years
- Shareholder approval secured at the Annual General Meeting held on August 28, 2026
- E-voting results and scrutinizer report finalized on August 31, 2026
- Auditor firm holds over 18 years of professional experience in audit, tax, and advisory
Sat Kartar Life Limited disclosed the voting results of its Annual General Meeting held on August 28, 2026. All six resolutions were approved with 100% of valid votes polled in favour, including the adoption of FY26 financial statements, declaration of final dividend, and re-appointment of statutory auditors M/S Nidhi Bansal and Co. Related-party transactions regarding COO remuneration and managerial remuneration under Section 197 were also approved after excluding interested promoter votes.
- All 6 AGM resolutions passed with 100% favourable votes of total valid votes polled
- Overall turnout for general resolutions stood at 65.99% (1,04,24,352 votes polled out of 1,57,95,276 total shares)
- Resolution 5 approving Related Party Transactions for COO remuneration passed with 4,38,200 valid non-promoter votes after 99,86,152 promoter votes were deemed invalid due to interest
- Final dividend for the financial year ended March 31, 2026, officially approved by shareholders
Sat Kartar Life Limited conducted its 14th Annual General Meeting on August 28, 2026, with 23 shareholders representing 66.12% of total voting power in attendance. Key resolutions tabled included the adoption of FY26 financial statements, approval of a final dividend of Rs 0.70 per share (FV Rs 10), and the re-appointment of M/s Nidhi Bansal & Co. as statutory auditors for a 5-year term up to FY31. Special business items included shareholder approvals for related party transactions and managerial remuneration. Voting results via CDSL e-voting will be declared within two working days.
- 23 shareholders holding 1,04,44,556 shares (66.12% of share capital) attended the virtual AGM
- Final dividend of Rs 0.70 per equity share (face value Rs 10) tabled for approval for FY26
- Re-appointment of M/s Nidhi Bansal & Co. as Statutory Auditors for 5 consecutive years up to FY31
- Voting results to be declared on NSE and company website within 2 working days
Sat Kartar Life Limited has announced a virtual one-to-one meeting with Prijal Investment scheduled for August 11, 2026. The company recently reported a March 2026 quarterly revenue of ₹110.62 crore with a net profit of ₹9.80 crore. Management is currently focused on scaling manufacturing utilization from 10% to 50% and expanding into the US market. No unpublished price sensitive information (UPSI) will be shared during this routine investor interaction.
- One-to-one virtual meeting scheduled for Tuesday, 11th August 2026, at 11:30 A.M. IST
- Interaction is specifically with Prijal Investment as per the regulatory filing
- Company reported a quarterly PAT of ₹9.80 crore for the period ending March 2026
- Manufacturing capacity utilization is currently scaling from 10% to 50% month-on-month
- Targeting a long-term growth rate of 25-30% through AI-driven sales and US expansion
Sat Kartar Life Limited is establishing a new 4,000 sq. ft. hospital-cum-therapy centre in Gurugram, Haryana, with an estimated investment of ₹1 crore. The facility will feature 10-15 beds and is slated to become operational by October 15, 2026, funded through IPO proceeds. This expansion aligns with the company's strategy to enter the high-margin Ayurvedic hospital segment, which targets 25-30% EBITDA margins. While the capex is small (~0.9%) relative to the March 2026 quarterly revenue of ₹110.62 crore, it represents a key vertical integration step.
- Investment of approximately ₹1 crore to be funded via IPO proceeds
- Proposed capacity addition of 10-15 beds in a 4,000 sq. ft. facility
- Expected commencement of operations by 15th October, 2026
- Targeting high-margin Ayurvedic hospital services with 25-30% EBITDA margins
- Strategic location in Sector 68, Gurugram to strengthen healthcare network
Sat Kartar Life Limited has announced the establishment of a new hospital-cum-therapy centre in Gurugram, Haryana, with an estimated investment of ₹1 crore. The facility, spanning 4,000 sq. ft., will have a capacity of 10-15 beds and is expected to be operational by October 15, 2026. This move aligns with the company's strategy to diversify into high-margin (25-30% EBITDA) Ayurvedic hospital services, funded entirely through IPO proceeds. This represents a vertical expansion from their existing D2C wellness product business into physical healthcare infrastructure.
- Estimated investment of approximately ₹1 crore to be funded via IPO proceeds
- Proposed bed capacity of 10-15 beds in a 4,000 sq. ft. covered facility
- Target operational date set for October 15, 2026, pending regulatory approvals
- Strategic expansion into Ayurvedic hospital services targeting 25-30% EBITDA margins
- Location finalized at Tower B, 68 Avenue, Sector 68, Gurugram
Sat Kartar Life Limited has scheduled its 14th Annual General Meeting (AGM) for August 28, 2026, at 10:00 AM IST via video conferencing. The company has dispatched physical letters to shareholders who have not registered their email IDs, providing them with the web link to the FY 2025-2026 Annual Report. This follows a March 2026 quarter where the company reported a revenue of ₹110.62 crore and a net profit of ₹9.80 crore. The filing is a standard procedural compliance under SEBI (LODR) Regulations.
- 14th Annual General Meeting (AGM) scheduled for August 28, 2026, at 10:00 AM IST.
- Annual Report for Financial Year 2025-2026 made available via a dedicated web link for all shareholders.
- Letters dispatched on August 3, 2026, to shareholders without registered email addresses.
- Company reported a quarterly net profit of ₹9.80 crore for the period ending March 2026.
Sat Kartar Life Limited has scheduled its 14th AGM for August 28, 2026, to approve a final dividend of ₹0.70 per share for FY 2025-26. The company is seeking shareholder approval for significant Related Party Transactions (RPT) totaling ₹164.5 crore for FY 2026-27, primarily for trade and marketing with subsidiaries. For the full year FY 2025-26, the company reported a net profit of ₹17.10 crore, a significant increase from ₹9.81 crore in the previous year. The record date for dividend eligibility is set for August 21, 2026.
- Proposed final dividend of ₹0.70 per equity share (7% of face value) for FY 2025-26
- Total Related Party Transactions (RPT) limit of ₹164.5 crore proposed for the 2026-27 fiscal year
- Individual RPT limits of ₹40 crore each established for subsidiaries Plantomed, Ajooni, Sat Kartar Ocean, and Sat Kartar USA
- Annual net profit for FY 2025-26 reported at ₹17.10 crore based on surplus accounts
- Re-appointment of M/s. Nidhi Bansal & Co. as Statutory Auditors for a five-year term until 2031
Sat Kartar Life Limited has recommended a final dividend of ₹0.70 per equity share (7% of face value) for the financial year ended March 31, 2026. The Board has fixed August 21, 2026, as the record date for determining shareholder eligibility for the dividend and AGM e-voting. The 14th Annual General Meeting is scheduled for August 28, 2026. This follows a March 2026 quarter where the company reported a net profit of ₹9.80 crore on revenue of ₹110.62 crore.
- Recommended a final dividend of ₹0.70 per equity share of face value ₹10 each
- Fixed August 21, 2026, as the record date for dividend payment and AGM e-voting
- Scheduled the 14th Annual General Meeting for August 28, 2026, via video conferencing
- Proposed re-appointment of M/S. Nidhi Bansal & Co. as statutory auditors for a 5-year term
- Reported March 2026 quarterly EPS of ₹6.22
Financial Performance
Revenue Growth by Segment
Standalone revenue reached INR 88.35 crores in H1 FY26, representing a 17% year-on-year growth. The company is targeting a trajectory of INR 300 crores by FY27 and INR 500 crores within three years, implying a required CAGR of approximately 40-50% to meet the long-term goal.
Geographic Revenue Split
The company currently covers over 11,600 pincodes across India. It has recently initiated international expansion by establishing a US subsidiary and opening international territories to drive future growth beyond the domestic market.
Profitability Margins
PAT margin saw a 100% improvement, rising from 5% in H1 FY25 to 8.81% in H1 FY26. The company targets a PAT margin of 9-10% for the full year FY26 and 12-15% by FY27, driven by operational excellence and disciplined spending.
EBITDA Margin
EBITDA margins improved by over 200 basis points in H1 FY26 compared to the previous period. Management is targeting a long-term EBITDA margin range of 15-20% as the business scales and benefits from operating leverage.
Capital Expenditure
The company has transitioned from an asset-light model to setting up its own manufacturing unit, which is now operational. The payback period for this manufacturing capex is estimated at 18 months due to high internal margins. Additionally, the company is investing in Ayurvedic hospitals with a revenue potential of INR 100 crores at 90% utilization.
Credit Rating & Borrowing
Not disclosed in available documents; however, the company operates on a negative working capital cycle and maintains an asset-light infrastructure for its core retail operations.
Operational Drivers
Raw Materials
Capsules and powders are the primary raw components, accounting for 50% of the company's top-line revenue. The company is moving to manufacture 50% of these requirements in-house to secure the supply chain.
Import Sources
Not specifically disclosed, though the company noted that supply chain stability is critical, as a 15-day stoppage could wipe out annual earnings due to high marketing spend.
Capacity Expansion
Current manufacturing is in a transition phase with utilization scaling from 10% to 50% month-on-month. Hospital operations are targeting 80-90% capacity utilization within 12 months of opening, with a revenue target of INR 10,000 per operational bed.
Raw Material Costs
Raw materials for capsules and powders represent 25% of the total product cost. By manufacturing these in-house, the company expects to capture higher margins and mitigate supply chain risks that previously limited growth.
Manufacturing Efficiency
The new manufacturing unit aims to improve margins by capturing the value previously lost to third-party manufacturers. Efficiency is expected to rise as utilization moves toward the 50% mark in the near term.
Logistics & Distribution
Distribution is handled through a mix of D2C channels and third-party marketplaces like Amazon and Flipkart. The company is currently testing Quick Commerce (Blinkit) in Maharashtra to analyze cost-to-revenue efficiency.
Strategic Growth
Expected Growth Rate
25-30%
Growth Strategy
Growth will be achieved through an AI-driven model to improve data churning and sales conversion, vertical growth into Ayurvedic hospitals (25-30% EBITDA margins), and horizontal expansion into the US market. The company also plans to reduce ad spend by 100-200 bps through AI-optimized targeting.
Products & Services
Ayurvedic wellness products including capsules and powders, flagship sexual health supplements like Liv Muztang, the Veda low-ticket product range, and Ayurvedic hospital services.
Brand Portfolio
Sat Kartar, Liv Muztang, Veda.
New Products/Services
The Veda range is being launched to convert the 90% of data that does not purchase high-ticket items. Hospital services are expected to be EBITDA accretive with 25-30% margins.
Market Expansion
Expansion into Maharashtra via Blinkit for Quick Commerce and the establishment of a US-based subsidiary for international D2C sales.
Market Share & Ranking
The company competes in a crowded market of 800+ D2C players and established giants like Dabur, Patanjali, and Himalaya.
Strategic Alliances
The company acquired Plantomed to bolster its product portfolio and manufacturing capabilities.
External Factors
Industry Trends
The industry is shifting toward AI/ML for personalized Ayurvedic treatments and digital-first distribution. Digital marketing spend in the sector is growing at 14% YoY, significantly outpacing television growth at 5%.
Competitive Landscape
Intense competition from over 800 D2C players and traditional leaders like Dabur, Patanjali, and Himalaya who have strong existing distribution networks.
Competitive Moat
The moat is built on a unique combination of human-centric engagement, multilingual capabilities, and deep Ayurvedic expertise. This is further strengthened by a 'data powerhouse' of categorized consumer health data.
Macro Economic Sensitivity
The wellness market is expanding rapidly, but the company is sensitive to digital advertising inflation, as digital marketing accounts for 42% of total industry ad spend.
Consumer Behavior
There is a strong consumer preference shift toward natural and effective health solutions, though conversion rates for healthcare search ads remain low at 2.6%.
Geopolitical Risks
Indo-Pak relations are a specific risk factor that has previously 'disturbed' the business trajectory and supply chain logistics.
Regulatory & Governance
Industry Regulations
Operations are subject to Ministry of Ayush approvals for hospital facilities and manufacturing standards for Ayurvedic products. The company is also regularizing its board composition in line with SEBI LODR regulations.
Taxation Policy Impact
The company declared a final dividend of INR 0.70 per equity share (7% of face value) for FY25, subject to standard TDS rates for resident and non-resident shareholders.
Legal Contingencies
The company is undergoing a variation in the objects and terms of utilization of its Initial Public Offering (IPO) proceeds, which required shareholder approval via postal ballot.
Risk Analysis
Key Uncertainties
The primary uncertainty is the gestation period for new hospitals (6-8 months to breakeven) and the successful integration of the AI model to reduce high customer acquisition costs.
Geographic Concentration Risk
Currently heavily concentrated in India (11,600 pincodes), with active steps being taken to diversify into the US market.
Third Party Dependencies
Historically dependent on third-party manufacturers for 100% of products; currently reducing this to 50% to mitigate supply chain 'hits'.
Technology Obsolescence Risk
The company is proactively addressing tech risks by moving from a standard D2C model to an AI-driven data powerhouse for better lead churning.
Credit & Counterparty Risk
Minimal credit risk due to the D2C nature of the business and negative working capital cycle.
